Co-Diagnostics Inc

Company Profile

Co-Diagnostics Inc had its IPO on 2017-07-12 under the ticker symbol CODX.

The company operates in the Healthcare sector and Medical Devices industry. Co-Diagnostics Inc has a staff strength of 145 employees.

Stock update

Shares of Co-Diagnostics Inc opened at $1.22 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.21 - $1.24, and closed at $1.21.

This is a 0% increase from the previous day's closing price.

A total volume of 43,722 shares were traded at the close of the day’s session.

In the last one week, shares of Co-Diagnostics Inc have increased by +0.83%.

Co-Diagnostics Inc's Key Ratios

Co-Diagnostics Inc has a market cap of $32.99 million, indicating a price to book ratio of 0.6346 and a price to sales ratio of 1.4524.

In the last 12-months Co-Diagnostics Inc’s revenue was $12.12 million with a gross profit of $28.74 million and an EBITDA of $-30014636. The EBITDA ratio measures Co-Diagnostics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Co-Diagnostics Inc’s operating margin was -258.77% while its return on assets stood at -13.61% with a return of equity of -24.55%.

In Q1, Co-Diagnostics Inc’s quarterly earnings growth was a positive 30.8% while revenue growth was a negative 97.3%.

Co-Diagnostics Inc’s PE and PEG Ratio

Forward PE

16

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.02 per share while it has a forward price to earnings multiple of 16 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Co-Diagnostics Inc’s profitability.

Co-Diagnostics Inc stock is trading at a EV to sales ratio of 0.1837 and a EV to EBITDA ratio of -0.0407. Its price to sales ratio in the trailing 12-months stood at 1.4524.

Co-Diagnostics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$117.00 million

Total Liabilities

$3.61 million

Operating Cash Flow

$-10632792.00

Capital Expenditure

$179944

Dividend Payout Ratio

0%

Co-Diagnostics Inc ended 2024 with $117.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $117.00 million while shareholder equity stood at $110.63 million.

Co-Diagnostics Inc ended 2024 with $203335.00 in deferred long-term liabilities, $3.61 million in other current liabilities, 34823.00 in common stock, $34.18 million in retained earnings and $0 in goodwill. Its cash balance stood at $6.36 million and cash and short-term investments were $75.28 million. The company’s total short-term debt was $277,290 while long-term debt stood at $0.

Co-Diagnostics Inc’s total current assets stands at $85.92 million while long-term investments were $950001.00 and short-term investments were $68.92 million. Its net receivables were $4.44 million compared to accounts payable of $829819.00 and inventory worth $5.29 million.

In 2024, Co-Diagnostics Inc's operating cash flow was $-10632792.00 while its capital expenditure stood at $179944.

Comparatively, Co-Diagnostics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.21

52-Week High

$7.13

52-Week Low

$0.975

Analyst Target Price

$4.67

Co-Diagnostics Inc stock is currently trading at $1.21 per share. It touched a 52-week high of $7.13 and a 52-week low of $7.13. Analysts tracking the stock have a 12-month average target price of $4.67.

Its 50-day moving average was $1.3 and 200-day moving average was $1.91 The short ratio stood at 7.09 indicating a short percent outstanding of 0%.

Around 107.1% of the company’s stock are held by insiders while 1942.7% are held by institutions.